PDF(Pubmed)
Abstract：
In our study, we observed the long-term survival outcomes investigated for HER2-0 and HER2-low-positive breast cancer patients who received neoadjuvant chemotherapy. Between 1998 and 2020, 10,333 patients with primary breast cancer were treated, including 1373 patients with HER2-0 or HER2-low-positive disease with neoadjuvant chemotherapy. Descriptive analyses were performed, and logistic regression models and survival analyses were calculated for disease-free survival (DFS) and overall survival (OS). Among the 1373 patients, 930 (67.73%) had HER2-low-positive and 443 (32.27%) had HER2-0 tumors. Patients with HER2-0 tumors had a significantly better pathological complete response, 29.25% vs. 20.09%, and pathological complete response/in situ, 31.97% vs. 24.08%, than patients with HER2-low-positive tumors (p < 0.001; p = 0.003), regardless of the hormone receptor (HR) status. No statistically significant differences were observed for the HR-positive (p = 0.315; p = 0.43) or HR-negative subgroups (p = 0.573; p = 0.931). DFS and OS were significantly longer for HR-positive, HER2-low-positive patients (log-rank p = 0.02; p = 0.012). OS was significantly longer for HR-negative, HER2-0 patients (log-rank p = 0.032). No significant DFS differences were found for the HR-negative cohort (log-rank p = 0.232). For the overall cohort, no significant differences were noted between HER2-low-positive and HER2-0 patients, either for DFS (log-rank p = 0.220) or OS (log-rank p = 0.403). These results show different survival outcomes for HER2-0 and HER2-low-positive tumors relative to HR status. These different cohorts can be identified using standardized immunohistochemistry, even retrospectively.
摘要：
在我们的研究中,我们观察了接受新辅助化疗的HER2-0和HER2低阳性乳腺癌患者的长期生存结局.在1998年至2020年期间，共治疗了10333例原发性乳腺癌患者，包括1373例HER2-0或HER2低阳性疾病的新辅助化疗患者。进行了描述性分析，计算无病生存期(DFS)和总生存期(OS)的logistic回归模型和生存分析.在1373名患者中，930例(67.73%)有HER2低阳性，443例(32.27%)有HER2-0肿瘤。HER2-0肿瘤患者有明显更好的病理完全缓解,29.25%与20.09%,和病理完全反应/原位，31.97%vs.24.08%,比HER2低阳性肿瘤患者（p<0.001；p=0.003），无论激素受体（HR）状态。HR阳性（p=0.315；p=0.43）或HR阴性亚组（p=0.573；p=0.931）没有观察到统计学上的显着差异。HR阳性的DFS和OS明显延长，HER2-低阳性患者(log-rankp=0.02;p=0.012)。HR阴性的OS明显更长，HER2-0患者(log-rankp=0.032)。在HR阴性队列中没有发现显著的DFS差异(log-rankp=0.232)。对于整个队列，HER2低阳性和HER2-0患者之间没有显著差异，对于DFS(对数秩p=0.220)或OS(对数秩p=0.403)。这些结果显示HER2-0和HER2低阳性肿瘤相对于HR状态的不同存活结果。可以使用标准化的免疫组织化学来识别这些不同的队列，甚至是回顾性的。
